0001104659-19-032921.txt : 20190530 0001104659-19-032921.hdr.sgml : 20190530 20190530214810 ACCESSION NUMBER: 0001104659-19-032921 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190528 FILED AS OF DATE: 20190530 DATE AS OF CHANGE: 20190530 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vertex Global Healthcare Fund I Pte Ltd. CENTRAL INDEX KEY: 0001663140 STATE OF INCORPORATION: U0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 19868408 BUSINESS ADDRESS: STREET 1: 250 NORTH BRIDGE ROAD STREET 2: #05-01 RAFFLES CITY TOWER CITY: SINGAPORE STATE: U0 ZIP: 179101 BUSINESS PHONE: 6568288088 MAIL ADDRESS: STREET 1: 250 NORTH BRIDGE ROAD STREET 2: #05-01 RAFFLES CITY TOWER CITY: SINGAPORE STATE: U0 ZIP: 179101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 4 1 a4.xml 4 X0306 4 2019-05-28 0 0001761612 BICYCLE THERAPEUTICS plc BCYC 0001663140 Vertex Global Healthcare Fund I Pte Ltd. C/O BICYCLE THERAPEUTICS PLC B900, BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB 22 3AT UNITED KINGDOM 0 0 1 0 Ordinary Shares 2019-05-28 4 C 0 1272733 A 1272733 D Ordinary Shares 2019-05-28 4 X 0 141668 A 1414401 D Ordinary Shares 2019-05-28 4 C 0 206767 A 1621168 D Series B1 Preferred Shares 2019-05-28 4 C 0 1272733 D Ordinary Shares 1272733 0 D Series B1 Preferred Shares Warrants 2019-05-28 4 X 0 141668 D Ordinary Shares 141668 0 D Series B2 Preferred Shares 2019-05-28 4 C 0 206767 D Ordinary Shares 206767 0 D Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering. /s/ Chua Kee Lock By:Chua Kee Lock Title: Director 2019-05-30